Unknown

Dataset Information

A post-marketing safety assessment of COVID-19 mRNA vaccination for serious adverse outcomes using administrative claims data linked with vaccination registry in a city of Japan.


ABSTRACT:

Introduction

The safety profiles of COVID-19 vaccines are incompletely evaluated in Japan.

Objectives

To examine the risk of serious adverse effects after COVID-19 mRNA vaccination (BNT162b2 and mRNA-1273) in cohort studies and self-controlled case series (SCCS).

Methods

Using an administrative claims database linked with the COVID-19 vaccination registry in a city in Japan between September 2020 and September 2021, we identified health insurance enrolees aged ≥ 18 years. We evaluated the risk of acute myocardial infarction, appendicitis, Bell's palsy, convulsions/seizures, disseminated intravascular coagulation, immune thrombocytopenia, pulmonary embolism, haemorrhagic or ischemic stroke, venous thromboembolism, and all-cause mortality, 21 days following any COVID-19

SUBMITTER: Takeuchi Y 

PROVIDER: S-EPMC9637511 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature